BioNTech's Founders Set for Exit as Restructuring and Pipeline Progress Collide
Veröffentlicht: 15.05.2026 um 09:52 Uhr, Redaktion boerse-global.de
BioNTech’s transformation from COVID-19 vaccine maker to pure-play oncology group is accelerating at every level – from the boardroom to the factory floor. The Mainz-based biotech posted a first-quarter net loss of €531.9 million on revenue of just €118.1 million, underscoring the urgency of a pivot that now also involves the departure of its founding duo.
Ugur Sahin and Ă–zlem TĂĽreci, who together built BioNTech into a pandemic-era household name, plan to step down from their executive roles at the end of 2026. The pair intend to launch a new independent biotech focused on mRNA innovation, with BioNTech contributing technology and retaining a minority stake. The news has rattled investors already grappling with a steep revenue decline as Comirnaty sales shift fully to partner Pfizer by end of next year.
Shares closed the previous session at €78.70 before slipping to €78.35 in recent trading, leaving the stock roughly 10% below its 200-day moving average and down about 5% year to date. Despite the sell-off, the company’s largest shareholder, ATHOS, maintains a roughly 40% stake and has signaled continued support.
BioNTech’s supervisory board has proposed expanding from six to eight members, adding two seats reserved for experts in oncology, clinical development, and product commercialization. Three existing members are standing for re-election. The company is also seeking authorization for a new capital framework of up to €129.5 million – equivalent to 50% of current share capital. No dividend will be paid; the 2025 retained earnings of approximately €6.9 billion will remain in the business.
Should investors sell immediately? Or is it worth buying BioNTech?
The governance overhaul arrives alongside tangible pipeline advances. In the first quarter, BioNTech initiated five registrational studies for Pumitamig across indications including triple-negative breast cancer, colorectal carcinoma, and lung cancer. Seven late-stage data packages are expected this year. Separately, the antibody-drug conjugate Trastuzumab Pamirtecan posted a confirmed response rate of roughly 49% in a 145-patient phase II trial for HER2-positive endometrial cancer. BioNTech and partner DualityBio plan to file for FDA approval in 2026, subject to regulatory feedback. Another candidate, Gotistobart, an anti-CTLA-4 antibody, received FDA orphan drug designation in January for squamous cell lung carcinoma.
To fund this oncology push, BioNTech is slashing costs aggressively. Roughly 1,860 positions are being eliminated, and production sites in Idar-Oberstein, Marburg, a CureVac facility, and Singapore are being closed or downsized. Additional locations may be sold. The restructuring is expected to yield annual savings of roughly $585 million by 2029, though another target cited by management is €500 million. The company’s full-year revenue guidance stands at $2.3 billion to $2.6 billion, and it reaffirmed its goal of having 15 phase III studies active by the end of 2026.
Financially, the group remains well capitalised. Its cash position was reported at $19.6 billion in the first-quarter filing, while elsewhere the figure has been cited as nearly €17 billion. On that solid base, the board has authorized a new share buyback program of up to $1 billion, valid through May 2027.
BioNTech at a turning point? This analysis reveals what investors need to know now.
BioNTech’s shareholder meeting is being held virtually today with no physical attendance. The agenda is forward-looking: a restructured board, a leaner cost base, and a pipeline that must now prove it can stand on its own. With the founders preparing to exit and the last COVID-era factories closing, the market is watching for clinical evidence – not governance resolutions – to validate the company’s new direction.
Ad
BioNTech Stock: New Analysis - 15 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
